LAUSR

Primary hepatic squamous cell carcinoma (SCC) is a rare, highly aggressive liver cancer that is associated with intrahepatic stone, liver cirrhosis, hepatic cyst, and Caroli’s disease. At present, there are no settled therapy guidelines for primary hepatic SCC. Patients with successful surgical resection have a tumorfree survival of approximately 69 months.(1,2) Immune checkpoint inhibitors are a promising treatment for multiple tumor types, with significant efficacy and manageable toxicity.(3) We report on a case of primary hepatic SCC following resection that responded dramatically to camrelizumab, a programmed cell death 1 (PD1) inhibitor, with tumorfree survival of 14 months to date.